Description

Lentikats biotechnology is efficient in immobilzing various enzymes used in the food and pharmaceutical industries. Bioconversions, biotransformations and hydrolytic processes result in significant increases in yield.

Lentikats biotechnology is an easy, inexpensive solution that provides robust biocatalysts based on Lentikats biocatalytic technology. The production of biocatalysts alone eliminates many financially demanding processes requisite to biocatalyst production in the industry to date. Lentikats biotechnology provides the option of  immobilizing free enzymes used in biotransformations (resulting in operational savings) as well as replacing existing, cross-linked enzyme aggregates or enzymes immobilized on a stable carrier.

Immobilzations of Lentikats biocatalytic forms dramatically increase the yield of enzymatic activity in the immobilization process, reducing costs for biocatalytic production and the final product while increasing the mechanical stability and simplifying seperability. The newly produced biocatalyst then possesses excellent physio-mechanical properties. Free enzymes provide the added advantage of reusability. Implementing Lentikats biotechnology is easy and does not require additional investments.

Lentikats technology advantages can be summarized in several fundamental points:

• Improved Return on Investment (higher product yield, dramatic reductions in investment costs)
• Quality and Durability (biocatalysts are reusable, high stability in production processes)
• Increased Profits (reduced operational costs and increased revenues)
• Environmentally Friendly Processes (lower production of waste and byproducts)
• Lower Entrepeneurial Risk for Our Clients

Products and solutions

Lentikats biotechnology is applicable in the following processes:

• glucose syrup production from starch substrates (immobilized glucoamylase)
• glucose-fructose syrup production from sucrose (immobilized invertase)
• D-galactose production from lactose (from whey by immobilzing β-galactosidase, pharmaceutic quality)
• galactooligosaccharide production from lactose (from whey by immobilizing β-galactosidase)

 Technical leaf: B-galactosidase

We currently provide the following products and solutions in the pharmaceutical industry:

• 6-aminopenicillin acid production (6-APK) (immobilized enzymes with G-acylase penicillin activity)
• 7-aminodeacetoxycefalosporovic acid production (7-ADCK) (immobilized enzymes with G-acylase penicillin activity)
• syntheticized amoxiciline (Pen G controlled hydrolysis with the aid of immobilized enzymes G- acylase penicillin activity)

 Technical leaf: Pen G-acylase

References

• Pilot unit of the batch and continual pilot plant for biotransformation with immobilized enzyme with PGA activity: Microbiological Institute (MBÚ) Prague, pharmaceutical industry.
• Pilot tests with immobilized enzyme with PGA activity in the foreign companies.
• Supplies of Lentikats biocatalyst with PGA activity for the company Fermenta Biotech Ltd., India.

F.A.Q.

How does the preparation of Lentikats robust biocatalysts differ from the preparation of biocatalysts currently in use? The price of biocatalysts used in various fusions, biotransformations, bioconversions and hydrolytic processes represents around 10-30% of the final price of intermediate or end products. The current, global trend in the area of biocatalytic development involves increasing the specific activity of biocatalysts to meet the current demand for high stability enzymes and to deviate from the use of costly, commercial carriers (i.e. Eupergit and Sepabeads). Lentikats biotechnology provides robust biocatalysts that are relatively simple and very economical with relevance to requisite costs for the production of most industrial biocatalysts currently in use. Immobilization to poyvinyalkohol (PVA) matrixes provides increased yields in enzyme activity when compared with other methods of seperating enzymes. To profile the demanding processes involved in commercially used enzymes today (i.e. in β-substance antibiotic processes) it is first necessary to describe individual steps:

- 24 kg of cellular catalytic dry matter (DW) with 300 U/g DW  specified activity is prepared from 1200 l of  fermented volume